Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Asset Writedowns and Impairment (2023 - 2025)

Sangamo Therapeutics has reported Asset Writedowns and Impairment over the past 4 years, most recently at $13.2 million for Q4 2025.

  • Quarterly results put Asset Writedowns and Impairment at $13.2 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $13.2 million (up 139.72% YoY), and the annual figure for FY2025 was $13.2 million, up 139.72%.
  • Asset Writedowns and Impairment for Q4 2025 was $13.2 million at Sangamo Therapeutics, up from $1.2 million in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for SGMO hit a ceiling of $51.3 million in Q2 2023 and a floor of $200000.0 in Q4 2023.
  • Median Asset Writedowns and Impairment over the past 3 years was $4.3 million (2023), compared with a mean of $12.4 million.
  • Peak annual rise in Asset Writedowns and Impairment hit 3.55% in 2024, while the deepest fall reached 97.72% in 2024.
  • Sangamo Therapeutics' Asset Writedowns and Impairment stood at $200000.0 in 2023, then skyrocketed by 486.0% to $1.2 million in 2024, then skyrocketed by 1029.27% to $13.2 million in 2025.
  • The last three reported values for Asset Writedowns and Impairment were $13.2 million (Q4 2025), $1.2 million (Q2 2024), and $4.3 million (Q1 2024) per Business Quant data.